Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant drop in short interest in April. As of April 30th, there was short interest totaling 6,999 shares, a drop of 69.2% from the April 15th total of 22,704 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 33,057 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Bolt Biotherapeutics

Large investors have recently made changes to their positions in the company. Squarepoint Ops LLC grew its holdings in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC purchased a new stake in Bolt Biotherapeutics in the 3rd quarter worth about $85,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics in the third quarter worth about $89,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Bolt Biotherapeutics in the fourth quarter worth about $112,000. Finally, T3 Companies LLC purchased a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at approximately $208,000. 86.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BOLT has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a report on Friday, March 13th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $41.00.

Bolt Biotherapeutics Trading Down 0.9%

NASDAQ:BOLT traded down $0.05 during midday trading on Thursday, hitting $4.79. 7,058 shares of the company traded hands, compared to its average volume of 25,300. The firm’s fifty day moving average is $4.59 and its 200-day moving average is $5.13. Bolt Biotherapeutics has a 12-month low of $3.91 and a 12-month high of $9.25. The firm has a market capitalization of $9.20 million, a P/E ratio of -0.29 and a beta of 1.10. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.76.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 91.06% and a negative net margin of 455.15%.The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $1.50 million. On average, sell-side analysts predict that Bolt Biotherapeutics will post -9.54 EPS for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.